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A STUDY ON CHRONIC OBSTRUCTIVE PULMONARY DISEASES 
 
 AUTHOR: Prof. Dr.K.Nagarajan, Dr.SUGUMAR T 
  Thanjavur Medical College, Thanjavur- 613004  
 
BACKGROUND: In India , Chronic Obstructive Pulmonary Diseases rank 
second only after pulmonary tuberculosis ,  which is the leading  disease 
affecting the respiratory system. The incidence of Chronic Obstructive 
Pulmonary Disease  is high in the middle-aged subjects.This  study documents 
the  age and sex distribution of Chronic Obstructive Pulmonary Diseases and 
the exposure of  risk factors of COPD in Thanjavur population. Further more 
this study is to elucidate the relationship of clinical symptom and spirometry 
abnormalities and also the incidence of right heart failure in Chronic 
Obstructive Pulmonary Diseases. 
AIMS & OBJECTIVES: To study the age and sex distribution and the 
prevalence of  various risk factors and to correlate the clinical symptoms with 
spirometry abnormalities  in Chronic Obstructive Pulmonary Diseases. And  to 
study the clinical incidence of Right Heart failure in Chronic Obstructive 
Pulmonary Diseases. 
METHODS: 
This study was conducted at Department of Medicine and 
Thoracic Medicine, Thanjavur Medical College during the period of Jan 2015 to 
August 2015. Number of patients in this study is 60 cases.  Those who complied 
with the inclusion and exclusion criteria were subjected to detailed history 
taking and clinical examination and necessary blood tests and imaging 
RESULTS: COPD has male predominance as evidenced by 9:1 ratio of Male to 
Female due to high prevalence of smoking habits observed in males. Cigarette 
smoking was the major risk factor for COPD in this study. Cough / Cough with 
expectoration of sputum was the major clinical symptom observed in this study. 
Acting accessory muscles of respiration with pursed lip breathing was the major 
clinical sign observed in this study. 
CONCLUSION: COPD is the disease of aged as majority of patients in the 
present study  belong to the age group of 50 – 80 years. Spirometry is the 
mandatory investigation to diagnose and assess the severity of COPD. Most 
number of cases had severe airway obstruction which was not reversible. High 
flattened diaphragm and hyperlucent lungs were the most common chest x-ray 
finding observed in this study. 
KEY WORDS 
Spirometry, chronic obstructive lung disease, pack years 
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INTRODUCTION 
 
The Global Initiative for chronic obstructive lung disease (GOLD) defines 
chronic obstructive pulmonary disease as “stage of a disease with irreversible airflow 
limitation”  
Chronic Obstructive Pulmonary Diseases encompasses emphysema , chronic 
bronchitis and small airway disease  
(I)Emphysema is a condition in which there is irreversible  distension of 
airways distal to terminal bronchioles due to destruction of the wall with absent 
fibrosis 
(ii) Chronic Bronchitis is a condition in which there is presence of  productive 
cough on most of the days in 3 months in a year for two years. 
(iii) Small airway disease 2is a condition resulting  due to narrowing of small 
bronchioles . 
Bronchial asthma is not included here as most of the times airway changes are 
reversible 3. Chronic  Bronchitis and emphysema are mostly found to be coexistent   
as they  share the same  etiological factors . In other terms they are found to be a 
continuum in pathological scale because   as  years pass by chronic bronchitis get 
transferred in to  emphysema. 
According to GOLD,  Chronic Obstructive Pulmonary Diseases ,is a fast 
growing disease of the  world. At present ,  it is the  sixth cause of death but by 2020 it 
is estimated to become the third most common cause of death  world wide . 1 
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In India , Chronic Obstructive Pulmonary Diseases rank second only after 
pulmonary tuberculosis ,  which is the leading  disease affecting the respiratory 
system. 19 
The incidence of Chronic Obstructive Pulmonary Disease  is high in the 
middle-aged subjects with males being the most commonly affected due to increased  
frequency of   smoking among them . 22 
The disease prevalence is documented to be equal  in  both rural and urban 
regions . 19 
In this age of urbanisation and acculturation increase in smoking habits , 
increase in usage of gasoline automobiles and emergence of large scale  industries 
leading to Air contamination has led to increase in incidence of  Chronic Obstructive 
Pulmonary Diseases. 
  Chronic Obstructive Pulmonary Diseases has also been found to be linked 
with Low birth weight, malnutrition, recurrent respiratory infections in young age. 24 
Spirometry is the most robust test of airflow limitation in patients with Chronic 
Obstructive Pulmonary Diseases. 3 
A low FEV1  (FEV1<80%) with FEV1  / FVC ratio < 0.7 and < 15% 
reversibility of airflow obstruction to bronchodialators is the diagnostic criteria for 
COPD. 2(FEV1 – Forced Expiratory Volume in 1 sec. FVC – Forced Vital Capacity) 
This study was conducted at Thanjavur Medical College during the period of 
January 2015 to June 2015. This  study documents the  age and sex distribution of 
Chronic Obstructive Pulmonary Diseases and the exposure of  risk factors of COPD in 
Thanjavur population  
15 
 
 
 
Further more this study is to elucidate the relationship of clinical symptom and 
spirometry abnormalities and also the incidence of right heart failure in Chronic 
Obstructive Pulmonary Diseases. 
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AIM OF THE STUDY 
 
1. To study the age and sex distribution in Chronic Obstructive Pulmonary 
Diseases. 
 
2. To study the prevalence of various risk factors in Chronic Obstructive 
Pulmonary Diseases. 
 
3. To correlate the clinical symptoms with spirometry abnormalities in Chronic 
Obstructive Pulmonary Diseases. 
 
4. To study the clinical incidence of Right Heart failure in Chronic Obstructive 
Pulmonary Diseases. 
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REVIEW OF LITERATURE 
 
Chronic obstructive pulmonary disease have been long studied  from the times 
of Laennec   . Though there has been many mechanical explanations of the disease,  
the association with smoking was not  made untill the start of  first half of the 20th 
century . But the association of heart failure with lung disease has been well 
established from earlier times.  
The earliest documentation of imbalance of enzymes and Anti enzymes as risk 
factor of emphysema was made  by OPIE , et al in 1905.3 
Then there were various other research works on emphysema . One such was 
done by Kountz and Alexander in 1934 which concluded that heart was most 
commonly affected in emphysema .Another in 1950s by Liebow et al proposed a 
vascular atrophy model  of the disease . In 1960 Gross and his associates observed the 
presence α1 antitrypsin deficiency in emphysema patients leading to the development 
of proteinase and antiproteinase  hypothesis in emphysema . 
For the first time in year 1956 , the term chronic bronchitis was used by 
Medical research council in its journal for a condition with chronic cough with 
expectoration were other causes like pulmonary tuberculosis and bronchiectasis were 
excluded .  
The relationship between smoking with chronic cough and  sputum production 
was established by Higgins in year 1959. The resultant  pathological changes in 
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airways, due to smoking was observed by Owen and Campell in late 1960s  . 
There has been numerous works on effects of chronic obstructive disease on 
cardiovascular system some of those significant studies are described below. 
 In 1971 Boushy SF et al., studied 108 patients of Chronic Obstructive 
Pulmonary Diseases. The ECG was correlated with pulmonary function Test and 
haemodynamic data. 
In 1972 Benjamin Burrows et al, done a seven year study of 50 cases of 
Chronic Obstructive Pulmonary Diseases whose cardiac status had been evaluated by 
cardiac catheterization when they were stable, showed that their longevity was 
inversely related with pulmonary vascular resistance. 
In 1973 Bougly and Colleagues published a series of papers on prognosis 
factors in Chronic Obstructive Pulmonary Diseases and prognosis values of lung 
function test in Chronic Obstructive Pulmonary Diseases. 
In 1981 Matthay et al listed the electro cardio graphic changes characteristic of 
RV and RA enlargement in COPD and cor  pulmonale. 
In 1987 Danchin N et al., used 2D echocardiography to study right side cardiac 
parameter and RV hypertrophy and showed the correlation between Echocardiography 
changes and clinical symptoms. 
In 1990 Migures M et al showed that usefulness of pulsed Doppler 
Echocardiography to detect pulmonary artery hypertension in patients with COPD. 
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EPIDEMIOLOGY 
Chronic Obstructive Pulmonary Diseases is responsible for considerable 
morbidity and mortality in the community especially among the older people. This 
disease places a major burden on  the resources of health care system because of their 
protracted course spanning over long period of time.  
COPD is a preventable disease and thus is  of considerable public health 
importance . 
Males are the most commonly affected due to high prevalence of smoking 
among  them compared to females. 
Exacerbation of the COPD occurs more during winter season due to the 
increase in  environmental trigger  factors in that season .  
PREVALENCE IN INDIA 
Chronic Obstructive Pulmonary Diseases is the second most common lung 
disorder after pulmonary tuberculosis. 
Incidence is higher in males due to higher prevalence of smoking rates among 
them . It is a disease of middle aged and elderly people and is  less common below the 
age of 35 years. 
Previous Studies conducted in other parts of the country, reported that the 
prevalence of chronic bronchitis was as high as 16% in people above 40 years of age . 
Due to extremes of climate in North India , they are found to have higher prevalence 
of  COPD compared to South India  .  
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Another study by Bhattacharya et al showed that the prevalence of chronic 
bronchitis in the age greater than  30 years was 57 / 1000 in a rural population . The 
study also documented male preponderance and the incidence of the disease directly 
proportional to the increasing age and number of pack years of smoking. 
PREVALENCE IN WESTERN COUNTRIES: 
In USA, it is estimated that there are around 16 million cases of COPD of 
whom about 14 million have  chronic bronchitis and other 2 million have  
emphysema. The   Male : Female ratio ranges from 4 – 6% / 1 – 3%. It is the third 
leading cause of death in U.S.  with around 1 lakh per  year .  
In UK, a prospective study involving 40,000 medical practitioners, showed that 
death due to chronic bronchitis was higher in smokers and was directly proportional to 
the duration of smoking. 
 
AETIOLOGY 
Chronic Obstructive Pulmonary Diseases is characterized  by areduced Forced 
Expiratory Volume in 1st second (FEV1) and it progresses with accelerated rate of 
decline in  FEV1.The reduction in FEV1  can occur by any of the  three pathways. 
1. In case of disturbed childhood growth and development, lower peak is 
attained in early adulthood followed by  a normal rate of decline with 
ageing. This can be seen in case of early childhood infection and in case of 
exposure to passive smoking.  
2. There will be a  normal growth and development with premature peak in 
adulthood due to asthma or passive smoking and subsequent normal  decline 
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.  
3. There will be a  normal attainment of  growth and development and  
subsequent adulthood peak but followed by  accelerated decline. This occurs 
due to  active smoking and  due to environmental exposures. 
 
RISK FACTORS: 
Smoking 
Cigarette smoking is the principal cause of disease in about 90% of patients 
with COPD . There is a dose dependent  response relationship between the number of 
pack-years of tobacco consumed and morbidity and mortality due to COPD. Pipe and 
cigar smokers are found to have reduced morbidity ratios compared to cigarettes, due 
to much lesser amount of inhaled toxicants with their use  . There is still now no clear 
cut evidence between the usage of  Electronic cigarettes and  incidence COPD. 
According to the British Thoracic Society guidelines most of the COPD patients with 
have at least 20 pack years of smoking history. The highest annual rate of decline in 
FEV1 in an average cigarette smoker is about 50ml, which is nearly double the 
average value of decline  in nonsmokers.s 
In nonsmokers,  the decline in FEV1 begins at mid 30s years  which may occur 
earlier than this age  in smokers. Stoppage of  cigarette smoking decrease the rate of 
decline in FEV1 but it does not produce  improvement in FEV1. 
Cigarette smoking has many harmful effects which includes the impairment of 
ciliary movements of respiratory epithelium,  inhibition  of alveolar macrophage 
function  and the continuous irritant action  leads to hyperplasia and hypertrophy of 
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mucus secreting glands lining the respiratory tract . The inhaled toxicants from 
Cigarette smoke also inhibits anti-proteases resulting in increased activity of 
proteolytic enzymes released from  polymorphonuclear leukocytes . Smoking is  also 
associated with increased airway responsiveness, this is linked  with rapid progression 
of COPD in these patients . The  earliest  mechanical defect identified in a smoker is  
obstruction of small airways . 
 
Air Pollution 
Air pollution is the next other common risk factor linked with COPD. This 
association is best demonstrated by the increase in the incidence  and mortality in  
COPD patients  in heavily industrialized urban areas. The  heavy pollution with sulfur 
dioxide and particulate matter is linked with increased episodes of exacerbations of 
bronchitis . 
The traditional cooking fuels such as wood, cow dung cake, etc., along with 
poorly ventilated houses in most of under developed countries contributes to the 
development of  chronic bronchitis. 
Socio Economic Status 
There is a strong association between socio economic status and respiratory 
symptoms , as occupation is linked with respiratory symptoms , this was demonstrated  
in a study in which  twins were included as subjects by Hrubec  et Al .  There  are  
many other studies which observes  an inverse relationship  between per capita 
income and the  obstructive lung disease. 
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Occupation 
Chronic bronchitis is more prevalent in workers who  are engaged  in 
occupation exposing them to inorganic or organic dusts, or to  other  noxious gases. 
There are surveys which  have demonstrated  an accelerated decline in lung function 
in workers  for example who are employed at plastic plants and in those  exposed  to 
Toluene disouganate etc. Exposure to cadmium has been directly linked to the 
development of emphysema.  
 
Recurrent Respiratory Infections 
The occurence of acute respiratory illness are higher in frequency in patients 
with chronic bronchitis. The Epidemiological studies however have implicated , 
recurrent respiratory illness as one of the major factors associated with development 
and  progression of chronic airway obstructive disease . 
 
Airway hyper responsiveness and atopy: 
Though airway hyper responsiveness is a definitive feature of asthma , it is also 
seen in many COPD patients but with less than 15% of reversibility of obstruction  by  
usage of bronchodilators. 
 
Growth And Nutrition 
There are evident Studies that show malnutrition accelerates decline in 
ventilatory function. There is also evidence that severe viral pneumonia early in life 
may lead to chronic obstruction of  small airways. 
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GENETIC FACTORS: 
α1, Antitrypsin Deficiency 
α1 AntiTrypsin (α1AT) is a polymorphic glycoprotein which is responsible for 
the majority of anti-protease activity in the serum. The genetic material of this protein 
is mapped on chromosome 14q 32 . The most commonest alleles resulting in 
deficiency is termed as ZZ (Cor PiZZPhenotype) results from a singleamino acid 
substitution Glu → Lysin the position 342 , which causes spontaneous polymerization 
of the polypeptide,  leading to impairment in release  of the protein into circulation 
from the liver. 
It is most common in people of European descent with incidence 1:2000 
compared  to 1:7000  in the people of African and Asian lineage. α1AT deficiency 
accounts for only  2% of observed  cases of emphysema. These patients present with 
early development of emphysema,  chronic bronchitis or bronchiectasis. They present 
usually in early forth decade of life with cough and dyspnea. Nearly 80% of this 
population have  family history of lung disease with autosomal recessive inheritance. 
Pathologically the panacinar emphysema predominates and radiographic changes are 
more common in lower lobes. 
 Tobacco smoking is an extremely important cofactor for development of 
disease in α1 AT deficiency. The average decline of FEV1  is 100-130ml / yr for 
smokers and 50 to80ml / yr for ex-smokers of lifetime non-smokers. They  are also at 
increased risk of developing hepatic cirrhosis. 
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PATHOLOGY 
 
 
The pathologic changes of COPD involves large and small airways and the 
terminal respiratory unit. 
-Hypertrophy of mucus producing glands. 
-goblet cell hyperplasia 
-reduced and sluggish movements of cilia 
-mucosal edema 
-hypertrophy of smooth muscles of bronchus 
-reduced calibre of air spaces 
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mechanisms of airway obstruction in COPD 
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Pathogenesis of chronic bronchitis  
 
 
 
 
 
 
 
 
 
 
 
The major site of airflow limitation is seen in small airways . The narrowing of 
airways are due to  goblet cell hyperplasia, infiltration of mucosal and submucosal 
layer by inflammatory cells, oedema, reactionary peribronchial fibrosis, intraluminal 
mucus plugs and increase in smooth muscle density. 
In the large cartilaginous airways, chronic bronchitis is associated with 
hypertrophy of submucosal mucus producing glands. These  anatomic changes can be 
assessed by  Reid index which is a ratio  of submucosal glands thickness to that of 
bronchial wall. In case of  chronic bronchitis patients  it is 0.52 ± 0.08otherwise 
normally it's around 0.44± 0.09. 
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Pathogenesis of emphysema  
The initial step in development of Emphysema is the increase in the number 
and size of alveolar fenestrate which eventually results in destruction of alveolar 
septae and their attachments to terminal  respiratory bronchioles are lost .In 
centriacinar emphysema the distension and destruction are mainly limited to the 
respiratory bronchioles with relatively less changes peripherally in the acinus. 
Panacinar emphysema involves both central and peripheral portions of acinus. 
Chronic exposure to cigarette smokes, fumes and dust leads to  the recruitment 
of  inflammatory cells in to the terminal air spaces of the lung. These cells then release 
elastolytic proteinases that damage the extra cellular matrix of the lung. 
The ineffective control of destruction of lung parenchyma  result in 
emphysema. 
 
PATHOPHYSIOLOGY 
Airflow limitation: 
Airflow limitation and increased airway resistance is caused by loss of elastic 
recoiling of lung during passive exhalation due to destruction of alveolar walls , or  
due to increased collapsibility of small airways through loss of radial traction on 
airways, or to increased resistance due to intrinsic narrowing of small airways. 
 
Hyperinflation: 
The residual volume and the functional residual capacity (FRC) are  higher 
than normal. In addition prolongation of expiration is associated with obstruction ,  
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leads to dynamic increase in Functional residual capacity  (dynamic 
hyperinflation).Dynamic hyperinflation in turn contributes to discomfort associated 
with air flow obstruction by flattening of diaphragm . 
 
Impaired Gas Exchange: 
Ventilation and perfusion mismatching is always present. When the 
mismatching is severe, impairment of gas exchange is reflected as decreased PaO2 in  
the arterial blood gas analysis. The mismatch is due to  Small airway narrowing 
leading to  decrease in ventilation of their distal alveolar acini were the  alveolar 
capillaries remain intact . 
Pulmonary Circulation in COPD 
Pulmonary arterial hypertension develops late in the course of COPD due to  
the development of hypoxia and usually hypercapnia. It is the major cardiovascular 
complication of COPD and is associated with the development of right ventricular 
hypertrophy (cor pulmonale) . It has a  poor prognosis. 
 
Factors contributing to pulmonary artery hypertension in COPD 
(i) ABNORMAL BLOOD GAS TENSIONS 
Hypoxia 
In COPD there is a negative correlation between oxygen saturation of the blood 
and pulmonary artery pressure. Hypoxemia is known to be a potent pulmonary 
arteriolar constrictor .As the   disease progresses in severity , there is more arterial 
desaturation which results in increase in pulmonary artery pressure. The acute 
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worsening of pulmonary hypertension is linked with  COPD  exacerbation. Pulmonary 
artery pressure (Ppa) can also increase acutely  during rapid eye movement of sleep 
which is associated with hypoxia , and it has been suggested that recurrent nocturnal 
pulmonary hypertension can result in pathologic changes in pulmonary vessels and 
fixed hypertension. 
 
Hypercapnea: 
In patients with COPD there is a positive correlation between arterial CO2 
pressure (PaCO2) and pulmonary artery pressure. The mechanism could be a change 
in lung mechanics due to hyperventilation induced by hypercapnea or the potentiation 
of hypoxic pulmonary vascoconstriction. 
 
Acidemia: 
Hypoxia and acidemia act synergistically to produce pulmonary 
vasoconstriction in patients with COPD. Thus for a given oxygen saturation, the mean 
Ppa is higher with associated increase in arterial hydrogen ion concentration. 
 
(ii) EFFECTS OF ABNORMAL PULMONARY MECHANICS 
Changes in airway resistance may augment pulmonary vascular resistance and 
increase in pulmonary artery pressure, correlating with decrease in FEV1. 
 
(iii) EFFECTS OF INCREASED CARDIAC OUTPUT 
In patients with COPD (in whom the vascular bed may be reduced) even small 
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increase in flow that occurs during exercise may increase pulmonary artery pressure. 
 
(iv) EFFECTS OF BLOOD VISCOSITY 
Polycythemia can develop secondary to chronic hypoxia in COPD patients, this 
contributes to blood viscosity which also adds up to the pulmonary arterial 
hypertension. 
 
(v) ROLE OF PULMONARY ENDOTHELIUM 
Endothelial dysfunction causes reduced nitric oxide synthesis which  leads to  
hypoxia resulting in development of pulmonary artery hypertension. . 
Thus the role of nitric oxide which prevents the increase in pulmonary vascular 
resistance is lost in this disease. Nitric oxide also inhibits cell proliferation in the 
pulmonary vessel walls and hence prevents the vascular remodeling. Circulating 
levels of endothelin  has found to be increased in patients with COPD and pulmonary 
hypertension. 
 
PATHOLOGY 
The changes in pulmonary circulation occur characteristically in the pulmonary 
arteries in patients with COPD. In the patients with COPD characteristic changes .An 
early change is the increased intimal thickness in small pulmonary arteries that occur 
due to accumulation of smooth muscles that are laid down longitudinally along the 
length of the vessel. The medial hypertrophy in muscular pulmonary vessels, has also 
been reported in patients of COPD who develop sustained pulmonary arterial 
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hypertension. Pulmonary thromboses may also occur in patients with COPD which  
may be secondary to peripheral airway inflammation. 
These structural changes rather than simply hypoxia ,vasoconstriction is the 
major factor in the development of sustained pulmonary hypertension in patients with 
COPD. 
 
PULMONARY HAEMODYNAMICS COPD 
Pulmonary hemodynamics depends on the severity of the disease . in mild 
cases , pulmonary artery pressure is normal iat rest and is moderately elevated during 
exercise .Cardiac parameters such as output , systolic and diastolic pressures are also 
normal.  
In case increase in severity associated with chronic hypoxia and hypercapnia  , 
pulmonary artery pressure shoots up even at rest. However in cases of clinically stable 
severe COPD  pulmonary artery pressures are only moderately elevated . 
 
CONSEQUENCES OF PULMONARY HYPERTENSION IN 
COPD 
Chronic bronchitis and emphysema usually coexist pathologically. Those 
patients with either predominant chronic bronchitis or emphysema from a minority at 
the either ends of the disease spectrum of COPD. 
The blue and bloated type also know as type B or non fighter was though to 
characterize the bronchial type of disease. 
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These patients have hypoxemia, hypercapnea and secondary polycythemia, 
leading to early development of pulmonary hypertension .. In these cases there occur 
frequent repeated episodes in right heart failure associated with right ventricular 
hypertrophy 
In contrast the pink and puffing variety also known as type A or fighter, were 
though to represent the emphysematous patients characterized by severe 
breathlessness, but with preservation of blood gas values and thus no pulmonary 
hypertension, at least until the later stages of disease. 
It was now known that the degree of mucous gland hypertrophy indicative of 
chronic bronchitis was similar whatsoever the clinical pattern and that more than 50% 
of patients with blue and bloated clinical pattern had severe emphysema. 
 
THE NATURAL HISTORY OF UNTREATED PULMONARY 
HYPERTENSION IN COPD 
The progression of pulmonary hypertension in COPD is slow. The elevation in 
pulmonary artery pressure is small and it rarely reaches the levels of primary 
pulmonary hypertension. Weitzenblum and colleagues found a change of 3mm Hg in 
the pulmonary artery pressure per year and 33% of patients showed a rise greater than 
5mm Hg over 5 years who had worsening of hypoxemia and hypercapnia  
Inspite of the slow progression the presence of pulmonary artery hypertension 
implies a poor prognosis. 
One study shows that the 4 years survival rate was 40% in patients with 
pulmonary hypertension compared to 72% in patients whose pulmonary artery 
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pressure was normal (less than 20mm Hg). 
The other variable which correlates significantly with survival are PaO2, 
PaCO2, FEV1 and the presence of peripheral oedema.  
  The pulmonary hypertension reflects the severity of the disease and predicts 
the  prognosis of COPD. 
 
COR PULMONALE 
Cor pulmonale is defined as right ventricular hypertrophy and dilatation 
secondary to pulmonary hypertension caused by disease of the lung parenchyma and / 
or pulmonary vasculature, unrelated to both sides of heart. 
In an  European study , enrolling large population showed  that incidence of 
right ventricular failure increases  as air flow limitation worsens in  COPD patients, 
that is 40% of patients had right ventricular failure when   FEV1 < 1.0L and  70%    
had failure when FEV1 <0.6L.  The prevalence of cor pulmonale is also higher in 
patients with hypercapnia ,  hypoxemia and polycthemia. 
In clinically stable COPD patients ,right ventricular function is near normal 
even with increased pulmonary artery pressure . But in clinically unstable patients in 
respiratory failure with failing right ventricular function the pulmonary artery pressure 
is very much increased compared to stable. 
There is increasing evidence that the oedema which develops late in the course 
of the disease in patients with COPD may not be entirely due to right ventricular 
failure. The fluid and electrolyte imbalance in  COPD is due to the presence of 
associated hypoxemia and hypercapnia. There is decrease in renal blood flow in 
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patients with hypoxic COPD due to the increase in release of catecholamines 
associated with hypercapnia. Arginine vasopressin levels are  high in patients with 
COPD compared to normal population. There is also evidence of activiation of rennin-
angiotensin-aldosterone axis. Thus  peripheral oedema. is a resultant of change in 
pulmonary hemodynamics interaction with fluid and electrolyte imbalance. 
 
CLINICAL FEATURES 
Symptoms 
The most common clinical presentation of COPD is  breathlessness on exertion 
mostly accompanied with wheeze and cough with thick productive sputum .Most 
patients have a smoking history of minimum 20 pack years before the presentation . 
The mean age is around fifth decade. 
Breathlessness is the  most debilitating of all symptoms ,which is due to   loss 
of lung function over time which is first noted on climbing or exertion. The presence 
of breathlessness indicates the extent of impairment of airway function. By the time 
when patient seeks the medical help FEV1 has fallen significantly . When FEV1 has 
fallen to 30% or less  breathlessness is generally present even  on minimal exertion.        
In most patients with COPD cough is the first symptom to appear and is the neglected 
one, leading to time lag for medical approach. Sputum is usually mucoid and thick in 
character, but becoming purulent during exacerbations, which is linked with bacterial 
infections. Though there is copious secretions only small amount of sputum less than 
60ml per day is expectorated  due to narrowing of airway and increased viscosity of 
secretions .  
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As the disease progresses the frequency and severity of  exacerbations  
increases .  
Wheezing is present but it is not specific and it does not indicate the severity of 
the obstruction  . 
Weight loss and anorexia are seen in severe COPD. 
Physical Signs 
These is no specific signs for the disease and expect that the signs depend on 
the degree of air flow limitation and over inflation. In early stage of the disease the 
only abnormal findings is wheeze on forced expiration. There can be inspiratory and 
expiratory coarse crackles associated with mucus production and cough . In case of 
forced expiratory time longer than 6 seconds in more advanced disease, the breathing 
pattern is characteristic with a prolonged expiratory phase. Some patients adopt 
pursed-lip breathing on expiration which reduces expiratory airway collapse and 
improves oxygenation . The use of accessory muscles of respiration like alae nasi , 
sternocleidomastoid is seen in advanced disease. They may also adopt the tripod 
position by leaning forward, supporting themselves with their arms  to fix the shoulder 
girdle and allowing the use of pectoralis and latissimus dorsi to augment  chest wall 
movements.  
In later stages of the disease the chest wall becomes barrel shaped with increase 
in anterior posterior diameter, horizontal ribs, prominence of the sternal angle and 
wide subcostal angle .  An inspiratory tracheal tug may be detected. 
 The  diaphragm also assumes a horizontal position which helps  to pull  the 
lower ribs during inspiration (Hoover’s sign). 
37 
 
On percussion there is reduced cardiac and hepatic dullness, due to over 
inflation of lungs 
Breath sounds may have a prolonged expiratory phase or can be diminished 
uniformly .  
COMPLICATIONS OF COPD 
Acute mucopurulent exacerbations with secondary infections 
Respiratory failure 
Pulmonary bullae formation 
Bullae rupture 
Pneumothorax 
Cor pulmonale 
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RADIOLOGY 
Chest X-ray: 
There are no specific findings for chronic bronchitis in plain chest x Ray . 
Bronchial wall thickening may be noted as parallel line opacities. 
 The following Radiographic features are seen in emphysema: 
 Share-sheath treeches. 
 Low flattened diaphragm: The border of the diaphragm in the midclavicular line 
below the seventh rib. 
 Height of patients lung being greater than 29.9 cm. 
 An obtuse costophrenic angle. 
 Reduction in size and number of pulmonary vessels particularly in periphery of 
lung. 
 Heart shadow is vertical and narrowed . 
 In lateral film , there can be increase in the retrosternal airspace. 
 
Computed tomography: 
The high resolution computed tomography has  greater sensitivity and 
specificity than plain chest X-ray for emphysema but  it is rarely required except for 
diagnosis of bronchiectasis and to rule out bullous lung disease. 
SPIROMETRY 
Because of imprecisions in the  clinical findings, objective evaluation for 
detecting the  presence,  assessing severity and reversibility of airflow obstruction is 
essential for the diagnostic evaluation of COPD. 
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Spirometry is the most  robust test of airflow limitation in patients  with 
COPD. 
Forced expiratory volume in one second (FEV1) is recommended as the 
measurement of choice as  
 FEV1 is a reliable objective measurement. 
 It is simple and relatively quick to measure in  all stages of the  disease. 
 The forced expiratory manoeuvre records FEV1and also FVC . FEV1 / FVC 
ratio less than 70% is diagnostic of airway obstruction. 
  FEV1 predicts future morbidity and mortality. 
 Serial measurement provides evidence of disease progression. 
Global initiative for chronic obstructive lung disease (GOLD) group has 
reclassified COPD in June 2003 based on spirometery  values. 
 
FLOW VOLUME LOOPS 
Expiratory flow  at  75%  or  50% of vital capacity have been used as a 
measure of airflow limitation and provide complementary information to the usual 
volume time plot. There are problems with the reproducibility of these measurements 
and hence not preferred for routine clinical use. 
 
Reversibility to bronchodilators 
Reversibility tests are important because 
1. It distinguishes those patients with marked reversibility (at least 12% or 200ml 
of FEV1) who have underlying asthma. 
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2. It aids  in future management. 
3. The FEV1 after bronchodilator is the best predictor of survival. 
It is usually recommended that the response to bronchodilators be assessed 
either using repeated doses from metered dose inhaler or via the nebulised route. 
 
DIFFUSING LIMIT OF LUNG CARBON MONOXIDE (DLCO) 
DLCO values are below normal in many patients with COPD .There is a 
relationship between gas transfer and microscopic emphysema but the severity of 
emphysema in an individual patient cannot be predicted from this. 
 
ARTERIAL BLOOD GAS ANALYSIS 
Measurement of arterial blood gas is essential in patients with COPD especially 
in exacerbations to assess  the degree of hypoxaemia and hypercapnia . 
       
OTHER TESTS 
Patients with pulmonary hypertension and  cor pulmonale with normal day 
time blood gases should be evaluated for nocturnal desaturation by overnight 
oximetry. 
α1- AT level are not routinely needed but should be obtained incase of 
occurrence of COPD  in non smokers, and in those associated  with bronchiectasis, 
cirrhosis without apparent risks, premature emphysema in patients under 40 years 
with unremitting disease and in individuals with family history of AT deficiency. 
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METHOD OF ASSESSING CARDIAC FUNCTION IN PATIENTS 
WITH COPD  
The pulmonary haemodynamics and right ventricular function an be assessed 
by measuring  pressure and flow which involves the use of invasive techniques like 
cardiac catheterizaiton. 
The non invasive techniques which  include radiography ,electrocardiography, 
echocardiography, radionucleide  ventriculography and magnetic resonance imaging 
have proved to be useful in assessing COPD patients . 
 
CLINICAL ASSESSMENT 
Clinical examination is relatively insensitive in  detecting pulmonary 
hypertension or right ventricular dysfunction in patients with COPD, as clinical signs 
are often obscured by  the hyperinflation of the lungs .  
Physical signs that indicate the presence of pulmonary hypertension are loud 
pulmonary component of S2 with early systolicclick,and an early diastolic murmur in 
case of  pulmonary regurgitation . 
Jugular venous pressure is difficult to assess in these patients due to large 
swings in the intrathoracic pressure. 
Peripheral oedema can be present due to other related causes such as 
hypoalbuminemia . 
A  left parasternal heave indicates right ventricular hypertrophy. The extra 
heart sounds and murmur of tricuspid regurgitation suggests right ventricular 
dysfunction, but these are again modified by hyperinflation. 
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CHEST X-RAY 
The pulmonary artery width≥ 20mm relates directly to the presence of 
pulmonary arterial hypertension .The high value for hilar cardiothoracic ratio has 95% 
sensitivity and 100% specificity for the presence of pulmonary hypertension in 
patients with COPD. 
These are used as initial screening test for the presence of pulmonary 
hypertension, but they do not  predict the level of pulmonary artery pressure in 
individual patients. 
 
ELECTROCARDIOGRAPHY 
The voluminous lungs have an insulating effect and thus  diminishes  
transmission of electrical potentials to the electrodes. The heart descends to a lower 
position in the thorax due to lowering of diaphragm and alters the position of heart 
relative to the conventional electrodes. 
The electrocardiography abnormalities in COPD and with right heart 
involvement  are 10 
 Decreased magnitude of  electrocardiograph wave deflections. 
 P-waves with right atrial enlargement,  p-pulmonale i.e., tall peaked P waves in 
II, III and  aVF (P wave > 2.5mm) 
 QRS abnormalities: Right axis deviation and QRS > 90*. At times with extreme 
northwest QRS axis there is the S1S2S3 syndrome. In precordial leads there is a 
general loss of R wave amplitude in all precordial leads. With right ventricular 
hypertrophy R/S amplitude in V6<V1.  
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 Tendency for  incomplete right bundle branch block. 
Electrocardiography appears to be specific but has a low sensitivity in  picking up 
right ventricular hypertrophy. 
 
ECHOCARDIOGRAPHY 
Because of the deficiencies of clinical examination in detecting pulmonary 
artery hypertension in patients who have COPD and because pulmonary artery 
pressure (Ppa) is a good predictor of prognosis in these individuals, a number of 
attempts have been made to develop noninvasive methods to estimate it. 
Echocardiographic measurements of systolic ,  diastolic and pulmonary pressures have 
been shown to correlate with Ppa measured by the cardiac catheterizaiton studies. 11 
The most useful and accurate method of estimating pulmonary artery pressure 
in patients with chronic obstructive pulmonary disease is systolic transtricuspid 
gradient calculated from tricuspid regurgitation detected by continuous wave Doppler 
echocardiography. Continuous wave Doppler determination of tricuspid regurgitation 
jet velocity and 
application of modified Bernoulli’s equation (TG = 4V2, in which V is the velocity of 
tricuspid regurgitation jet and TG is the systolic right ventricular to right atrial 
pressure gradient across the tricuspid valve) permits reliable estimation of pulmonary 
artery pressure . 
Two dimensional echocardiography can be used to assess right ventricular 
dimensions and wall thickenings and hence to detect right ventricular volume  and 
pressure over load in patients with COPD. 
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Echocardiography can again be used to assess progression of disease or 
response to treatment by serial measurements of pulmonary artery pressure and right 
heart parameters. 
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MANAGEMENT OF COPD 
I. Non Pharmacological measures. 
II. Pharmacological measures. 
III Ventilatory support 
I. Non Pharmacological Measures 
Health education: it can play a role in improving stills, ability to cope with 
illness. 
 
i. Smoking cessation. 
ii. Basic information about COPD. 
iii. Self management skills / pulmonary rehabilitation  
II. Pharmacological Measures 
i. Nicotine replacement therapy in the form of gum, transdermal patch or 
inhaler is helpful in quitting smoking. 
ii. The use of bupropion, a noradrenergic antidepressant, is associated with 
better abstinence rates. 
iii. Bronchodilators are the main stay in the management of COPD. 
iv. Inhaled therapy is the preferred route  
v. Choice between β2 agonist, anticholinergics,  theophylline or combination 
therapy depends on availability and individual response in terms of 
symptom relief and side effects. 
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vi. Bronchodilators are prescribed on as needed, or on a regular basis to 
prevent or reduce symptoms depending on stage. 
vii. Long acting bronchodilators are more effective and convenient than the 
short acting ones . 
viii. Combining bronchodilators of different groups  can improve efficacy and 
decrease the risk of side effects compared to increasing the dose of a 
single bronchodilator. 
ix. Roflumilast  phosphodiesterase 4 inhibitor has found to  reduce the 
frequency of exacerbations. 
 
VENTILATORY SUPPORT  
Indications of ventilatory support in COPD 
Severe respiratory failure 
Respiratory rate >35 
hypercarbia (PaCO2 >60 mmHg) 
Acidosis (pH <7.25) 
Respiratory arrest 
Altered mental status 
Hypotension,cardiac failure,shock 
 
Generally for COPD patients Non Invasive ventilation is prefered over  invasive 
ventilation due to difficult to wean from mechanical ventilation 
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NON-INVASIVE VENTILATORY SUPPORT IN COPD 
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INVASIVE VENTILATION IN COPD 
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GLUCOCORTICOSTEROIDS 
Inhaled glucocorticoids  are appropriate for symptomatic COPD patients with 
an FEV1< 50% predicted as it decreases the frequency of exacerbation .  
But at present there is controversial reports on its effect over mortality 
reduction .  
Present guidelines recommend a trial of 6 weeks to 3 months with inhaled 
steroids in patients with exacerbations more than  two per year  ,  to identify patients 
who may benefit from long term inhalation steroid therapy.  
Long term treatment with oral steroids is not recommended in COPD because 
of its unfavourable risk ratio and Some of the side effects seen with long term steroid 
therapy are as follows  
osteoporosis, 
weight gain 
,cataracts 
,glucose intolerance and  
increased incidence of infection 
 In case of acute exacerbations a 14 day course of 30 mg oral prednisolone is 
recommended by GOLD guidelines 
Hyperglycemia is common complication reported in patients receiving short 
course glucocorticoid therapy 
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HOME OXYGEN THERAPY (HOT) 
Long term oxygen administration (> 15 hours per day) to patients with chronic 
respiratory failure has shown increased  survival rates in these patients  .  
In Nocturnal oxygen treatment trial , it has shown that there is  significant 
reduction in pulmonary arterial pressure by use of   either continous or nocturnal 
oxygen therapy for 6 months .  
This study also showed that survival rate over next 8 years correlated with 
decrease in mean pulmonary arterial pressure during the first 6 months of treatment. 
Long term oxygen therapy is indicated in Resting hypoxia  were  
 PaO2 at or below 55 mmHg or SaO2 at or below 88% with or without 
hypercapnia or 
 PaO2 between 55 mmHg and 60 mmHg or 90 %  if there is evidence of 
pulmonary hypertension, peripheral oedema suggesting congestive heart failure, 
or polycythemia (Haematocrit > 55%). 
Home oxygen therapy can be supplied in the form of compressed gas cylinders 
or oxygen concentrators. Oxygen concentrators are most convenient and cost 
effective. 
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OTHER PHARAMACOLOGIC TREATMENT 
 
α1 ANTITRYPSIN AUGMENTATION THERAPY: 
Young  patients  with  severe α1  AT deficiency ( < 11mic. moles )  and  
established emphysema may be candidates for the same. 
 
ANTIBIOTICS: 
Bacterial infection is found  to be major precipitant of acute exacerbations . 
Recently azithromycin because of its antibiotic and anti inflammatory property has 
found to reduce exacerbation of COPD by administering daily dose.  
They play major role in the treatment of exacerbations  
 
VACCINES: 
Influenza vaccines  annually can reduce serious illness and death in  about 50% 
of  those affected . Polyvalent  pneumococcal vaccine is also has been recommended . 
 
Surgical interventions  
Lung volume reduction surgery Lung transplantation  
 
 
 
 
52 
 
MATERIALS AND METHODS 
This study was conducted at Department of Medicine and 
Thoracic Medicine, Thanjavur Medical College during the period of Jan 2015 to 
August 2015. 
 
TOTAL NUMBER OF PATIENTS IN THIS STUDY: - 
Number of patients in this study is 60 cases. 
INCLUSION CRITERIA: - 
The cases in this study have following characters: 
(i) Cases between the age group of 30 – 80 years of  both sexes. 
(ii) These cases having the symptoms suggestive of chronic airway obstruction 
like cough, cough with expectoration of sputum of more than 2 years 
duration, dyspnoea, and with (or) without swelling of both legs. 
(iii) Cases in whom clinical diagnosis of COPD was made. 
(iv) All the cases were subjected to spirometry and the presence of COPD was 
confirmed by post bronchodilator spirometry values of 
i. FEV1< 80%. 
ii. FEV1 / FVC < 0.7. 
iii. Reversibility of obstruction < 15%. 
(FEV1 – Forced Expiratory Volume in 1 sec. FVC – ForcedVitalCapacity) 
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EXCLUSION CRITERIA: - 
Case with history of  the following  diseases were excluded; 
(i) Bronchial Asthma. (ii) Pulmonary Tuberculosis. 
(iv) Suppurative lung disease           (iv) Systemic Hypertension. 
(v) CAHD.             (vi)  Primary Pulmonary Hypertension. 
(vii) Sleep Apnoea syndrome           (viii) Valvular Heart disease. 
 
PROCEDURE: 
With  above  inclusion  and  exclusion  criteria  a  proforma  wasprepared to 
meet the objectives of the study. 
 
GEOGRAPHIC DISTRIBUTION: 
Patients were from Thanjavur Town, Pattukottai, and rural areasof Thanjavur, 
Pattukottai and Ariyalur districts. 
All the patients were subjected as follows; 
1) Detailed History. 
2) Smoking History. i) Age at which smoking was started. 
ii) Pack – years was calculated by 
formula. 
 
Pack Years  =          no of  cigarrates smoked /day   x No. of years of smoking  
                                                   20 
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3) General examination and examination of Respiratory system, and other 
systems. 
4) Examination specifically for signs of right heart failure like raised JVP, 
congestive hepatomegaly and pedal edema. 
5) Conventional 12 lead Electro cardiography was taken for ECG changes of 
COPD and Right Heart failure. 
6) X-ray chest PA view and left lateral view. 
7) Spirometry: - Spirometry was performed when the patient was clinically 
stable. 
Test was performed with the patient comfortably seated, with clothes loosened. 
The patients were instructed to take a deep inspiration then close the lips around the 
mouth piece and blow out as hard and fast as possible, following deep inspiration. 
Volume was obtained on the vertical axis of recording paper and time on the 
horizontal axis. The curve which was obtained is referred to as forced vital capacity 
curve. 
Forced Vital Capacity (FVC) is the volume of air that can be forciblyexhaled 
(as fast as possible) after a maximal inspiration. It is expressed in litres. 
 
 
 
 
55 
 
 
Forced Expiratory Volume in one second (FEV1) 
It is defined as the volume of air expelled in the first second, from the start of 
maximum expiratory effort of the forced vital capacity. It is expressed in litres or 
percentage of predicted. 
 
Forced expiratory volume in one second as a percentage of forced 
vital capacity (FEV1 / FVC) 
It is the percentage of forced vital capacity which is expelled in the first one 
second of maximal expiratory effort. 
By using spirometry results patients were classified based on GOLD staging of 
COPD. Severity of clinical symptoms were correlated with GOLD staging of COPD. 
Pack Years of smoking was compared with severity of COPD. Patients who 
showed clinical signs of right heart failure were subjected to Echo cardiography for 
confirmation. In echocardiography Mean maximum TR velocity was recorded in 
mt/sec and inserted in to the modified Bernoulli’s equation (4v 2), thus calculating the 
trans tricuspid pressure gradient (TTPG) and the pulmonary artery pressure. 
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RESULTS AND OBSERVATION 
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The study population had predominantly males in the age  group of    50-70 years of 
age. 
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Table – 1 
 
The following table  shows the distribution in relation to the sex and percentage of 
prevalence among them . 
 
 
 
 
 
 
 
Age       
In Male Percentage Female Percentage Total Percentage 
Years       
31-40 3 5.5% - 0% 3 5% 
       
41-50 5 9.2% - 0% 5 8.3% 
       
51-60 16 29.6% 2 33.3% 18 30% 
       
61-70 21 38.8% 3 50% 24 40% 
       
71-80 9 16.6% 1 16.6% 10 16.6% 
       
Total 54 100 6 100 60 100 
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From the above table it is observed that the majority of cases among males 
were between 61 – 70 years of age constituting 38.8% and the minimum number of 
cases were in the age group of 31 – 40 constituting 5.5%. 
The results collected from this study was tabulated into different variates and 
incidence of each variate was calculated in percentage. 
Among females the majority of cases were in the age group of 61– 70 years 
constituting 40% and nil cases were obs erved in the age group of 31 – 50 years. 
Both sexes put together the maximum cases were in the age group of 61 – 70 
years constituting 40% of total cases an d minimum cases were observed in the age 
group of 31 – 40 years which constituted 5% of total cases. 
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PIE DIAGRAM SHOWING SEX DISTRIBUTION OF THE CASES 
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This diagram shows sex distribution of cases.A male preponderance was seen. 
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Sex distribution: 
Table – 2 
 
 
 
 
 
 
 
 
 
From the above table, it is observed that the majority of the patients in this 
present study were belong to male sex. 
The male to female ratio was 9:1. 
 
 
 
 
 
 
 
 
 
 No. of cases Percentage 
   
Male 54 90% 
   
Female 6 10% 
   
Total 60 100% 
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PIE DIAGRAM SHOWING GEOGRAPHIC DISTRIBUTION 
OF CASES 
70%
30%
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Urban
This diagram shows 70% of cases were rural people.
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Table showing geographical distribution 
 
GEOGRAPHICAL DISTRIBUTION: 
Table – 3 
Area No. of cases Male Female Percentage 
Rural 42 37 5 70% 
Urban 18 17 1 30% 
Total 60 54 6 100% 
 
 
It is observed from the above table 42 out of 60 cases were from the rural areas 
constituting 70% of the total cases. 18 cases from the urban area constituted only 30% 
of the total. 
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RISK FACTOR DISTRIBUTION 
Table -4 
 
 
(* Life partners of this two female patients were heavy smokers more than 20 
pack-years of smoking).From the above table it was noted that major risk 
factor for COPD in males constituted 92.5% in males and 86.6% of total 
cases. 
 
 
 
 
Risk factor Male % Female % Total Percentage  
         
 Active 50 92.5%   
52 
  
Smoking 
     
86.6% 
 
Passive 
  
2* 33.3% 
 
     
         
Air pollution 6 11.1% 2 33.3% 8 13.3%  
        
Chronic        
Respiratory 14 25.9% 3 50% 17 28.3%  
Infection        
Allergy 4 7.4% 1 16.6% 5 8.3%  
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BAR DIAGRAM SHOWING RISK FACTORS IN CASES 
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Chronic respiratory inspection which constituted 50% of risk factor in 
females and 28.3% of total cases. 
Air pollution constituted 13.3% of risk factor followed by allergy with 
constituted 8.3%. 
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BAR DIAGRAM SHOWING NO. OF CASES IN PACK YEAR OFSMOKING 
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this diagram outlays the distribution of pack years. 
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PACK YEARS INTENSITY OF SMOKING 
 
Table – 5 
Pack year No. of patients Percentage 
10 – 20 2 4% 
20 – 30 38 76% 
30 – 40 10 20% 
 
From the above table it can be observed that the majority of patients had more 
than 20 pack years of smoking which constituted 96% of total cases. 
All the patients in this table were active smokers and all the patients were male. 
67 
 
 
DURATION OF DISEASE 
Table – 6 
Disease Duration Males Females Total Percentage 
2– 5 years 2 - 2 3.3 
6 –10 years 4 - 4 6.6 
11– 15 years 19 3 22 36.6 
16– 20 years 23 2 25 41.6 
> 20 years 6 1 7 11.6 
Total 54 6 60 100% 
 
From the above table it is observed that majority of patients had more than 
10 years duration of disease. 
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Maximum number of cases were seen 16 – 20 years du ration of disease 
constituting 41.6% of cases. 
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DISTRIBUTION OF SYMPTOMS 
 
Table – 7 
 
Symptoms No of patients Percentage 
Cough 60 100% 
Cough with expectoration of sputum 
56 93.3% 
Wheeze 46 76.6% 
Breathlessness 52 86.6% 
Swelling both legs 5 8.3% 
 
From the above table it is noted that all the patients in this study had cough. 
Cough was the major symptom constituted 100% in this study. 
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BAR DIAGRAM SHOWING CLINICAL SYMPTOMS IN 
PERCENTAGE 
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 Cough with expectoration of sputum was present in 93.3% of 
cases.Breathlessness  which constituted 86.6% of cases.Wheeze  which constituted 
76.6% of cases. 
Swelling of both legs were observed in 8.3% of cases 
 
 
 
 
. 
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DISTRIBUTION OF CLINICAL SIGNS 
 
Table – 8 
 
Clinical signs No. of patients Male Female Percentage 
Cyanosis 4 3 1 6.6% 
Polycythemia 2 1 1 3.3% 
Accessory muscles 
working 24 20 4 40% 
Pedal oedema 5 4 1 8.3% 
Raised JVP 5 4 1 8.3% 
Congestive 
Hepatomegaly 5 4 1 8.3% 
 
From the above table it is observed that active accessory muscles of 
respiration (inter costal in drawing) was the major clinical sign observed in 40% of 
the cases. 
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BAR DIAGRAM SHOWING CLINICAL SIGNS IN PERCENTAGE 
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In this study polycythemia was observed in 3.3% of cases.Pedal oedema, 
Raised JVP and Congestive Hepatomegaly were observed in 8.3% of cases. 
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DISTRIBUTION OF RADIOLOGICAL FINDINGS 
 
Table – 9 
 
Chest x-ray No. of patients Percentage 
Low flattened diaphragm with 
hyperinflated lungs 39 65 
Obtuse costophrenic angle 30 50 
Reduction in no and size of 
pulmonary vessels in periphery 12 20 
Normal 12 20 
 
From the study it is observed that Low flattened diaphragm with 
hyperinflated lungs was the major radiological feature present in 65% of cases. 
50% of cases were shown obtuse costo phrenic angle in chestx-ray. 
20% of the patients in this study had Normal x-ray chest. 
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DISTRIBUTION OF ECG CHANGES IN VARIOUS STAGES OF 
COPD 
Stage of 
 
ECG 
changes     
Poor ‘R’ 
 
QRS > 
R/S < 
   
(GOLD 
    
Wave ‘P’ + 900 in V6<   
criteria) progression Pulmonale frontal 1 in 5 mm 
Tot
al  
 
in V1 – V 6 
 
plane 
V5 V6    
      
Stage I - - - - - -  
Stage II 3 - - - - 3  
Stage III 5 0 0 - - 5  
Stage IV 6 5 5 3 3 22  
Total 14 5 5 3 3 30  
 
From the above table it is observed that more number of ECG changes were 
seen in patients in Stage IV of COPD. 
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BAR DIAGRAM SHOWING ECG CHANGES IN COPD  
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 There was no ECG changes observed in patients with Stage I of COPD. 
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DISTRIBUTION OF ECG CHANGES 
 
Table – 11 
 
ECG changes Male Female Total Percentage 
Poor ‘R’ Wave progression in 
V1 – V 6 12 2 14 23.3% 
‘P’ Pulmonale 4 1 5 8.3% 
QRS > + 900 in frontal plane 4 1 5 8.3% 
R/S < 1 in V5 V6 2 1 3 5% 
V6< 5 mm 2 1 3 5% 
 
From the above table it is observed that most frequent ECG abnormality in 
this study was poor progression of ‘R’ wave which was observed in 23.3% of cases. 
8.3% of cases showed evidence of cor pulmonale like ‘P’ Pulmonale and 
right axis deviation.  
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DISTRIBUTION OF CASES IN GOLD STAGING OF COPD 
 
Table – 12 
 
 
 
 
 
From the above table, majority of the patients in the study were Gold Stage 
III of COPD showing severe airflow obstruction (FEV1 30% - 50%). 
GOLD stage of 
  No. of cases    
Severity 
     
Percentage 
 
COPD 
Male 
 
Female 
 
Total 
 
     
      
         
Stage I FEV1≥ 80% Mild 1  1  2 3.33%  
Stage II 
Moderate 17 
 
1 
 
18 30% 
 
Fev1   50% – 80% 
   
        
         
Stage III 
Severe 31 
 
3 
 
34 56.6% 
 
FEV1  30% – 50% 
   
        
Stage IV Very 
5 
 
1 
 
6 10% 
 
FEV1< 30% Severe 
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BAR DIAGRAM SHOWING GOLD STAGE OF COPD CASES  
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10% of the patients showed FEV1< 30% very severe air flow 
 
obstruction belonged to Stage IV of COPD. 
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PIE DIAGRAM SHOWING CLINICAL SIGNS OF RHF IN COPD 
 
CASES IN PERCENTAGE 
 
54
6
Male Female
 
 
 
Right heart failure was predominantly seen in male population which has the 
higher prevalence of  COPD . 
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DISTRIBUTION OF RIGHT HEART FAILURE IN COPD 
 
Table – 13 
 
Total No. of patients 
Patient with clinical signs of   
Right Heart Failure 
  
   
Percentage 
 
       
Male Female Total Male Female Total 
 
  
        
54 6 60 4 1 5 
8.33
%  
        
 
 
 
 
From the above table it is observed that 5 cases having the clinical 
features of right heart failure constituting 8.33% of total. 
 
All the 8.33% are also proved by echocardiography. 
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DISTRIBUTION OF RIGHT HEART FAILURE IN DURATION 
 
OF DISEASE 
 
Table - 14 
 
  No. of cases  
Duration of disease 
   
Male Female 
 
   
     
2 – 5 years - -  
6 –10 years - -  
11 – 15 years - -  
16 – 20 years 1 -  
> 20 years 3 1  
 Total 4 1  
 
 
 
 
From the above table it is observed more number of patients with right 
heart failure having disease more than 20 years of duration constituting 80% 
of the total cases of right heart failure in COPD. 
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DISCUSSION 
 
1.  Total number of cases were 60 in this study. 
AGE AND SEX: 
2. In the present study maximum number of cases were in the age group of 
61-70 years. This coincides well with the various study as follows, 
i) Wig K.L Guleira K. S et al 1964 study showed maximum number 
of cases in 55-65 years. 20 
ii) Higham MA Dawson et al at 2001 showed maximum number 
cases in 61-70years. 52 
iii) Suzzane Hurd et al showed maximum number of cases in 60-70 
years. 4 
 
3. In this study, it was noted the incidence of COPD was higher in males 
than females with male to female ratio of 9:1. 
Male cases accounted for 90% of the total cases in this study. This 
finding also coincides with the following studies, 
1. Trivedi H.S. et al study showed 80% of cases were 
male. 46 
2. Mieguere et al showed 93% of cases were male. 44 
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GEOGRAPHICAL DISTRIBUTION: 
In this study it is observed that 70% of patients were from rural areas 
and 30% were from urban areas. 
The study by Bhattacharya S.N. et al, 1975, also made similar 
observation. 21 
Anderson et al, 1963, made similar observation in his study. 54 
In spite of heavy Air pollution, the urban areas contributed only 30% of 
the cases in this study. 
 
RISK FACTORS: 
Among the various risk factors Smoking is the major risk factor 
accounted for 87% of the causative risk factor in this present study. 
Ashley F, Kannel WB et al, 1975, made similar observation. 54 
Burrows et al, 1979, made similar observation. 25 
Intensity of smoking was expressed in pack-years in this study. As the 
number of pack-years more than 20, increased predisposition to COPD was 
observed in many studies. 
In this study, most of the patients were 20-30 pack-years of smoking 
constituting 96% of the total. 
Higgins ITT et al, 1959, observed in his study 86% patients were 
more than 30 pack-years of smoking. 55 
Chronic respiratory infection which constituted 28.3% was the second 
major risk factor observed in this study, followed by Air Pollution and 
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Allergy. 
Burrows B et al, 1977, also made similar observation.In his 
study Chronic respiratory infection constituted 35%. 56 
Air pollution constituted 13.3% of risk factor and Allergy 8.3% of 
risk factors. 24 
 
DURATION OF DISEASES: 
In this present study of most of the cases were above 10 years of 
duration of the disease. 
Barnes BJ et al, 1999, in his study observed 55% had more than 
15 years. 57 
 
Symptoms: 
In this study cough and cough with expectoration of sputum was 
observed in 100% and 93% of cases respectively 
Burrows et al, 1979, made in his study 96% of patients had cough with 
exportation of sputum. 25 
Dyspnoea was observed in 86.6% cases. 
Altose MD et al, 1985, observed 90% of cases had dyspnoea. 58 
 
Physical signs: 
This study observed acting accessory muscles of respiration was the 
major physical sign observed in 40% of cases. 
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Polycythemia (Secondary to hypoxia) was observed in only 3.3% 
ofcases. 
Pedal oedema raised JVP and congestive hepatomegaly observered in 
8.3% of cases. 
 
Chest X-ray PA view: 
In this present study most common radiological finding in chest ,   X-
ray PA view was hyper inflated lungs with low flattened diaphragm which 
constituted 65% of cases. 
Thurlbeck WM et al, 1970, observed in his study 78% of the patients  
showed  radiological evidence of emphysema with chronic bronchitis. 59 
Normal X-ray chest was observed in 20% of cases. 
 
Electrocardiography: 
By electrocardiography poor progression of ‘R’ Wav e was the most 
frequent abnormality detected in this present study constituted 23.3%. 
8.3% of cases showed ‘P’ pulmonale and QRS axis > + 900 
R/S < 1 in V5 -V6 observed in 5% of cases. 
R wave in V6< 5 mm was observed in 3.3% of cases. 
Boushy SF et al., 1971, in his study observed that ‘P’ pulmonale 
and QRS axis > + 900 were the major ECG changes present in 12.5% of 
the patient. 10 
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It was observed from this study more number of cases with ECG 
changes were seen in Stage IV COPD. Which denoted that as the severity of 
COPD increases, ECG changes also increases. 
 
SPIROMETRY: 
In the study most number of patients were in GOLD Stage III 
COPD which constituted 56.6% of cases. The study by Higham et al 52 
showed that majority of patients were in Stage III (BTS Scheme for COPD) 
constituted 57 – 58% of cases. 
Renzeti AD et al, 1966 observed 76% of his cases belong to 
moderate to severe stages of COPD. 49 
 
Right Heart Failure: 
In this study it is observed that 8.3% of cases showed clinical evidence 
of right heart failure. All the patients who showed the clinical evidence of 
right heart failure were subjected to echocardiography and confirmed the 
presence of right heart failure. 
Mattay R et al, 1981, observed that 12.5% of his cases were 
showed evidence of cor pulmonale. 16 
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SUMMARY 
 
In this study on Chronic Obstructive Pulmonary Diseases the following 
facts were observed. 
COPD is the disease of aged as evidenced by majority of patients in 
the present study  belong to the age group of 50 – 80 years. 
COPD has male predominance as evidenced by 9:1 ratio of Male to 
Female due to high prevalence of smoking habits observed in males. 
Cigarette smoking was the major risk factor for COPD in this 
study. 
Cough / Cough with expectoration of sputum was the major clinical 
symptom observed in this study. 
Acting accessory muscles of respiration with pursed lip breathing was 
the major clinical sign observed in this study. 
Spirometry is the mandatory investigation to diagnose and assess the 
severity of COPD. 
Most number of cases had severe airway obstruction which was not 
reversible. 
High flattened diaphragm and hyper lucent lungs were the most 
common chest x-ray finding observed in this study. 
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Poor progression of ‘R’ wave in chest leads, P Pulmonale, QRS > + 
900, R wave in V6< 5mm and R/S < 1 in V5 V6 were the ECG changes 
observed in this study. 
 
The clinical incidence of Right heart failure in COPD in this study was 
5% which was confirmed by ECHO. 
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CONCLUSION 
 
1. Chronic Obstructive Pulmonary Diseases is a preventable disease as 
smoking is the major risk factor for Chronic Obstructive Pulmonary 
Diseases. 
 
2. Spirometry is mandatory to diagnose and assess the severity of Chronic 
Obstructive Pulmonary Diseases  
 
3. FEV1 was the single most important parameter in spirometry to diagnose 
Chronic Obstructive Pulmonary Diseases along with the less than 15% of 
reversibility of airflow obstruction to bronchodilators. 
 
4. Severity of Chronic Obstructive Pulmonary Diseases has direct relation 
with incidence of ECG changes in Chronic Obstructive Pulmonary 
Diseases. 
 
5. Clinical signs of right heart failure in Chronic Obstructive Pulmonary 
Diseases were effective in screening the patients for cor pulmonale. 
 
6. Right heart failure denotes severity and duration of Chronic Obstructive 
Pulmonary Diseases. 
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CONSENT FORM 
 
 
I __________________________________________ hereby give 
consent to participate in the study conducted by DR. SUGUMAR.T,  
Post graduate in the Department of General Medicine, Thanjavur 
Medical College & Hospital, Thanjavur – 613004 and to use my 
personal clinical data and result of investigation for the purpose of 
analysis and to study the nature of disease. I also give consent for further 
investigations.  
 
 
Place : 
Date : 
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PROFORMA 
STUDY ON COPD 
 
NAME: AGE: SEX:M/F 
ADDRESS:  
I.P / O.P. 
NO.: 
OCCUPATION: ECONOMY CLASS:  High 
       Middle 
       Low 
 
DURATION OF DISEASE 
 PRESENTING SYMPTOMS:  
 
 
 Cough 
 Cough with expectoration of sputum 
 Breathlessness 
 Wheeze 
 Chest  pain 
 Fever 
 Haemoptysis 
 Both Legs Swelling 
 Others (Specify) 
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RISK FACTORS AND TRIGGERS: 
 
 Smoking 
 
 Air Pollution like, Smoke / Fumes / Dust 
 
 Recurrent respiratory infection. 
 
 Atopy   and Allergy 
 
 
SMOKING HISTORY: ♦ Active ♦ Passive 
 
Active: ♦ Cigarette / Ciger / Beedi 
 
 Age at smoking started. 
 
 Intensity of smoking in Pack-years. 
 
Passive: ♦ Father / Husband / Son / Other (Specify Relation) 
 
♦ Pack-year of smoking 
 
Family History: (A) Bronchial asthma (B) COPD 
 
 
 
OTHER DISEASES: 
 
♦ Pulmonary TB ♦ CAHD ♦ HT ♦DM ♦ Valvular  Heart disease 
 
GENERAL EXAMINATION: 
 
Clinical signs: 
 
♦ Anemia ♦ Polycythemia ♦ Cyanosis 
 
 Accessory muscles of respiration active / normal 
 
 Pursed lip breathing present / absent 
 
♦ Lymph nodes ♦ Pedal oedema ♦ JVP 
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Vital signs: 
PR: BP: RR: 
 
Examination of systems: 
 
RS: Inspection 
 
Palpation 
 
Percussion 
 
Auscultation 
 
CVS: 
 
P/A: Congestive hepatomegaly present / absent  
 
 
Lab values 
     
i) Alb.  ii) Sugar  
iii) DC  iv) Hb% 
iv) Urea     
      
            Chest X ray   PA view   
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GOLD Stage  FEV1 
FEV1 / 
FVC 
       
 Stage I      
       
 Stage II      
      
           Stage III      
      
            Stage IV      
       
i) Normal     
 
 
ii) Poor progression of ‘R’ wave in chest leads 
 
iii) ‘P’ Pulmonale 
 
iv) QRS > + 900 
 
v) R / S in V5 - V6< 1 
 
vi) V6 R < 5mm 
 
♦ Echo: 
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 KEY TO MASTER CHART 
i. P / Y – Pack Years 
ii. C.R.I. – Chronic Respiratory Infection 
iii. SYMPTOMS 
 a – Cough 
 b – Cough with expectoration of sputum 
 c – Wheeze 
 d – Breathlessness 
 e – Both Legs swelling 
iv. SIGNS 
 a – Cyanosis 
 b – Polycythemia 
 c - Accessory muscles working 
 d - Pedal oedema 
 e - Raised JVP 
 f - Congestive Hepatomegaly 
v. ECG CHANGES 
 
a – Poor ‘R’ Wave progression in V1– V6 
b. - ‘ P’Pulmonale 
- QRS > + 900in frontal plane 
d. - R/S < 1 in V5V6 
e. - V6< 5 
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